Why is Veracyte, Inc. ?
- The company has been able to generate a Return on Equity (avg) of 0.76% signifying low profitability per unit of shareholders funds
- OPERATING CASH FLOW(Y) Highest at USD 108.24 MM
- RAW MATERIAL COST(Y) Fallen by -2.41% (YoY)
- CASH AND EQV(HY) Highest at USD 687.15 MM
- Over the past year, while the stock has generated a return of 4.47%, its profits have risen by 112.2% ; the PEG ratio of the company is 0.4
- These investors have better capability and resources to analyse fundamentals of companies than most retail investors.
- The stock has generated a return of 4.47% in the last 1 year, much lower than market (S&P 500) returns of 18.81%
How much should you hold?
- Overall Portfolio exposure to Veracyte, Inc. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Veracyte, Inc. for you?
High Risk, High Return
Quality key factors
Valuation Key Factors 
Technical key factors
Technical Movement
Highest at USD 108.24 MM
Fallen by -2.41% (YoY
Highest at USD 687.15 MM
Lowest at -25.92 %
Highest at 10.25 times
Highest at USD 131.87 MM
Highest at USD 28.38 MM
Highest at 21.52 %
Highest at USD 19.3 MM
Highest at USD 0.24
At USD 3.76 MM has Grown at -82.23%
Here's what is working for Veracyte, Inc.
Operating Cash Flows (USD MM)
Net Sales (USD MM)
Operating Profit (USD MM)
Operating Profit to Sales
Net Profit (USD MM)
EPS (USD)
Cash and Cash Equivalents
Debt-Equity Ratio
Debtors Turnover Ratio
Raw Material Cost as a percentage of Sales






